Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
2018
e15175Background: IPI is an approved immunotherapy for advanced melanoma; it has enhanced spontaneous immunity to NY-ESO-1, a cancer-testis antigen expressed by some melanomas. NY-ESO-1 vaccines ha...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI